Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 19/20 | 0.42 |
| ▸ | LPAR3 | Q9UBY5 | 13/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.40 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.40 |
| ▸ | ABCB4 | P21439 | 1/20 | 0.40 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.40 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.40 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17215361 | 0.93 | LPAR1 (0.49) | LPAR1LPAR3CYP2C9ABCC3ABCC4 | |
| SCHEMBL17215362 | 0.93 | LPAR1 (0.49) | LPAR1LPAR3CYP2C9ABCC3ABCC4 | |
| SCHEMBL17367397 | 0.91 | LPAR1 (0.49) | LPAR1LPAR3CYP2C9ABCC3ABCC4 | |
| SCHEMBL17367418 | 0.90 | LPAR1 (0.39) | LPAR1LPAR3CYP2C9ABCC3ABCC4 | |
| SCHEMBL17215862 | 0.90 | LPAR1 (0.40) | LPAR1LPAR3CYP2C9ABCC3ABCC4 | |
| SCHEMBL17215867 | 0.90 | LPAR1 (0.40) | LPAR1LPAR3CYP2C9ABCC3ABCC4 | |
| SCHEMBL17367402 | 0.89 | LPAR1 (0.41) | LPAR1LPAR3CYP2C9ABCC3ABCC4 | |
| SCHEMBL17367399 | 0.87 | LPAR1 (0.41) | LPAR1LPAR3CYP2C9ABCC3ABCC4 | |
| SCHEMBL17367400 | 0.86 | LPAR1 (0.41) | LPAR1LPAR3CYP2C9ABCC3ABCC4 | |
| SCHEMBL17367403 | 0.86 | LPAR1 (0.39) | LPAR1LPAR3CYP2C9ABCC3ABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150376160-A1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2015-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376160-A1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | LPAR3, LPAR1, LPAR2 | LPAR1 2/4885LPAR3 1/4885CYP2C9 2611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.